# Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Toripalimab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement

> **NCT07104604** · PHASE1 · RECRUITING · sponsor: **Affiliated Cancer Hospital of Shantou University Medical College** · enrollment: 59 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** Liposomal Irinotecan

## Key facts

- **NCT ID:** NCT07104604
- **Lead sponsor:** Affiliated Cancer Hospital of Shantou University Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 59 (ESTIMATED)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07104604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07104604, "Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Toripalimab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07104604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*